• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, February 3, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Reduced-dose gadobutrol vs standard-dose gadoterate for contrast-enhanced brain MRI

Bioengineer by Bioengineer
September 6, 2025
in Chemistry
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A 25% reduced gadobutrol dose demonstrated non-inferior efficacy versus 100%-standard dose of gadoterate for contrast-enhanced brain MRI, particularly in patients undergoing multiple contrast-enhanced examinations

Leesburg, VA, June 17, 2021–According to ARRS’ American Journal of Roentgenology (AJR), a reduced dose of gadobutrol is non-inferior to 100%-standard dose of gadoterate for contrast-enhanced brain MRI.

“A 25% reduced gadobutrol dose demonstrated non-inferior efficacy versus standard dose gadoterate for contrast-enhanced brain MRI,” corresponding author Jan Endrikat of Germany’s University Medical School of Saarland elaborated, “warranting particular consideration in patients undergoing multiple contrast-enhanced examinations.”

In this international, prospective, multicenter, open-label, crossover trial (LEADER-75), 141 patients (78 men, 63 women; mean age, 58.5 years) with known or suspected CNS pathology underwent contrast-enhanced brain MRI with standard-dose gadoterate (0.1 mmol/ kg). If an enhancing lesion was identified, a second MRI with reduced-dose gadobutrol (0.075 mmol/kg) was performed within 15 days.

Comparison of reduced-dose gadobutrol and standard-dose gadoterate versus unenhanced imaging demonstrated noninferiority using 20% margin for three primary efficacy measures: subjective lesion enhancement, lesion border delineation, lesion internal morphology.

Furthermore, in post-hoc analysis, mean readings for subjective lesion enhancement, lesion border delineation, and lesion internal morphology differed by less than 1%–supporting equivalence using a narrow ±5% margin.

“Various secondary variables also supported non-inferiority of reduced-dose gadobutrol,” the authors of the AJR article added.

###

Founded in 1900, the American Roentgen Ray Society (ARRS) is the first and oldest radiological society in North America, dedicated to the advancement of medicine through the profession of radiology and its allied sciences. An international forum for progress in medical imaging since the discovery of the x-ray, ARRS maintains its mission of improving health through a community committed to advancing knowledge and skills with an annual scientific meeting, monthly publication of the peer-reviewed American Journal of Roentgenology (AJR), quarterly issues of InPractice magazine, AJR Live Webinars and Podcasts, topical symposia, print and online educational materials, as well as awarding scholarships via The Roentgen Fund®.

Media Contact
Logan K. Young
[email protected]

Original Source

https://arrs.org/ARRSLIVE/Pressroom/PressReleases/Reduced_Gadobutrol_vs_Standard_Gadoterate_Contrast-Enhanced_Brain_MRI.aspx

Related Journal Article

http://dx.doi.org/10.2214/AJR.21.25924

Tags: Clinical TrialsDiagnosticsHealth Care Systems/ServicesMedicine/HealthneurobiologyNeurochemistryPharmaceutical ChemistryPharmaceutical Science
Share13Tweet8Share2ShareShareShare2

Related Posts

Cavendish Laboratory and FormationQ Partner to Launch Applied Quantum Program Powered by IonQ Technology

Cavendish Laboratory and FormationQ Partner to Launch Applied Quantum Program Powered by IonQ Technology

February 3, 2026
blank

Breakthrough in Solving a Classic Magnetism Mystery

February 3, 2026

UCLA Scientists Create Mineral Sunscreen That Minimizes White Residue

February 3, 2026

Discovering a Novel Class of Unusual One-Dimensional Particles

February 3, 2026
Please login to join discussion

POPULAR NEWS

  • Enhancing Spiritual Care Education in Nursing Programs

    158 shares
    Share 63 Tweet 40
  • Robotic Ureteral Reconstruction: A Novel Approach

    81 shares
    Share 32 Tweet 20
  • Digital Privacy: Health Data Control in Incarceration

    63 shares
    Share 25 Tweet 16
  • Study Reveals Lipid Accumulation in ME/CFS Cells

    57 shares
    Share 23 Tweet 14

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

SCAI Expert Opinion Highlights Advances in Wire-Free Angiography-Derived Physiology for Coronary Assessment

Engineered Bacteria Combat E. coli via Metabolic Competition

Tai Chi Improves Blood Pressure and Inflammation Control

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 73 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.